Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?

摘要: Preclinical evidence has been accumulating on the impact of DNA repair status sensitivity/resistance to anticancer agents in different tumor types, including lung cancer. The possibility predict response therapy, and specifically platinum agents, based specific functionality would enable tailor its use only those patients with maximum chances respond, avoiding burden toxicity ones lesser chances. We here reviewed clinical prognostic role markers and/or functional assays predicting a platinum-based chemotherapy cancer patients. Consequently, we focused proteins involved pathways repairing induced inter-strand intra-strand crosslinks. Most promising trials targeting nucleotide protein ERCC1 non-small cell later suffered from serious drawbacks. Nevertheless, these results spurred variety preclinical studies multitude alternative markers. However so far, no one analyzed can be considered reliable mature biomarker for selecting discuss reasons such failure which discloses novel strategies future.